友芝友生物-B(02496)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02496 友芝友生物-B

休市中 02-06 11:15:44

7.600

+0.000

0.00%

最高7.600	最低7.600	成交量4,000
今开7.600	昨收7.600	日振幅0.00%
总市值14.73亿	流通市值8.47亿	总股本1.94亿
成交额3.15万	换手率0.00%	流通股本1.11亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02496","market":"HK","secType":"STK","nameCN":"友芝友生物-B","latestPrice":7.6,"timestamp":1770347744878,"preClose":7.6,"halted":0,"volume":4000,"delay":0,"changeRate":0,"floatShares":111468814,"shares":193849200,"eps":-0.503479,"marketStatus":"休市中","change":0,"latestTime":"02-06 11:15:44","open":7.6,"high":7.6,"low":7.6,"amount":31520,"amplitude":0,"askPrice":7.9,"askSize":2000,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.441123,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770600600000},"marketStatusCode":7,"adr":0,"listingDate":1695571200000,"exchange":"SEHK","adjPreClose":7.6,"openAndCloseTimeList":[[1770341400000,1770350400000],[1770354000000,1770364800000]],"volumeRatio":0.5050505050505051,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02496","defaultTab":"news","newsList":[{"id":"2608360867","title":"友芝友生物-B(02496)：公司H股全流通获联交所授出上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2608360867","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608360867?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:06","pubTimestamp":1770214006,"startTime":"0","endTime":"0","summary":"友芝友生物-B(02496)发布公告，公司已于2026年2月4日获联交所批准6801.03万股H股( \n相当于根据转换并上市将予转换的公司非上市股份总数 )上市及买卖。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_13.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_13.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401772.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"友芝友生物-B(02496)：公司H股全流通获联交所授出上市批准","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02496","BK1161"],"gpt_icon":0},{"id":"1195242271","title":"友芝友生物-B宣布M701获FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1195242271","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195242271?lang=zh_cn&edition=full","pubTime":"2026-02-04 00:36","pubTimestamp":1770136568,"startTime":"0","endTime":"0","summary":"2月3日，武汉友芝友生物制药股份有限公司（02496.HK）宣布，其研发的M701已获得美国食品药品监督管理局（FDA）的新药临床试验申请（IND）批准。此次获批标志着该药物可进入临床开发阶段，为公司创新药管线的国际化布局奠定重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2608824493","title":"友芝友生物-B(02496)：M 701取得FDA的IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2608824493","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608824493?lang=zh_cn&edition=full","pubTime":"2026-02-03 18:09","pubTimestamp":1770113353,"startTime":"0","endTime":"0","summary":"智通财经APP讯，友芝友生物-B 发布公告，于2026年1月31日，注射用重组抗上皮细胞黏附分子和分化簇3人鼠嵌合双特异性抗体获美国食品药物管理局临床试验申请批准，标志着这款针对恶性胸腔积液的创新疗法迈入国际化临床开发新阶段，为全球患者带来新希望。M 701精准靶向Ep CAM和CD3，其中Ep CAM在上皮来源恶性胸腔积液肿瘤细胞中高频表达，是关键治疗靶点;CD3可激活机体抗肿瘤免疫，二者协同实现精准治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02496","IND","BK1161"],"gpt_icon":0},{"id":"2606766165","title":"友芝友生物-B盘中异动 急速上涨7.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606766165","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606766165?lang=zh_cn&edition=full","pubTime":"2026-01-28 10:31","pubTimestamp":1769567516,"startTime":"0","endTime":"0","summary":"2026年01月28日早盘10时31分，友芝友生物-B股票出现异动，股价大幅拉升7.61%。友芝友生物-B股票所在的生物技术行业中，整体涨幅为0.50%。其相关个股中，友芝友生物-B、MIRXES-B、创胜集团-B涨幅较大，振幅较大的相关个股有旺山旺水-B、维亚生物、复宏汉霖，振幅分别为12.30%、7.60%、7.23%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128103156a6b53e38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128103156a6b53e38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2606221662","title":"友芝友生物-B(02496)：中国证监会就公司H股全流通发出备案通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2606221662","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606221662?lang=zh_cn&edition=full","pubTime":"2026-01-26 18:01","pubTimestamp":1769421689,"startTime":"0","endTime":"0","summary":"智通财经APP讯，友芝友生物-B 发布公告，本公司近期已就H股全流通向中国证监会提交备案。根据备案通知，有关转换并上市的中国证监会备案已告完成，倘本公司拟于备案通知发出日期起 12个月内未完成转换并上市，拟继续推进的，则需向中国证监会提交更新后的备案。截至本公告日期，H股全流通及转换并上市的实施计划详情尚未最终落实。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397400.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"友芝友生物-B(02496)：中国证监会就公司H股全流通发出备案通知","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2605403773","title":"友芝友生物-B(02496)拟3688万元转让武汉市东湖新技术开发区土地使用权及建筑物","url":"https://stock-news.laohu8.com/highlight/detail?id=2605403773","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605403773?lang=zh_cn&edition=full","pubTime":"2026-01-23 22:06","pubTimestamp":1769177198,"startTime":"0","endTime":"0","summary":"智通财经APP讯，友芝友生物-B 公布，于2026年1月23日，武汉依瑞德与该公司订立转让协议，该公司拟向武汉依瑞德转让土地使用权及建筑物，代价约为人民币3688万元。据悉，土地及建筑物位于中国湖北省武汉市东湖新技术开发区高新三路以北、神墩三路以南，截至转让协议签署之日，土地的地盘面积约为25,533.4平方米，而建筑物的总楼面面积约为11,333.22平方米，为工业用途，土地使用权年期为50年，于2062年5月24日届满。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2595787728","title":"友芝友生物-B(02496)：石剑获选举为职工代表监事","url":"https://stock-news.laohu8.com/highlight/detail?id=2595787728","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595787728?lang=zh_cn&edition=full","pubTime":"2025-12-31 12:55","pubTimestamp":1767156917,"startTime":"0","endTime":"0","summary":"智通财经APP讯，友芝友生物-B(02496)发布公告，王涛博士因个人职业发展原因而辞去公司职工代表监事职务，自2025年12月31日起生效。公司转化医学部总监石剑博士于2025年12月31日获民主选举为第二届监事会职工代表监事。石博士的任期自2025年12月31日起生效，并将于第二届监事会结束时届满。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2593471543","title":"友芝友生物-B(02496)：Y225(艾美赛珠单抗注射液)取得NMPA的IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2593471543","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593471543?lang=zh_cn&edition=full","pubTime":"2025-12-24 19:37","pubTimestamp":1766576227,"startTime":"0","endTime":"0","summary":"智通财经APP讯，友芝友生物-B 发布公告，于2025年12月23日，其生物类似药Y225的临床试验申请已获中华人民共和国国家药品监督管理局批准。Y225是一种用于治疗A型血友病的双特异性抗体舒友立乐生物类似药。本次获批的临床试验是一项在健康成年人中进行的随机、双盲、单剂量、平行比较舒友立乐与Y225在健康男性受试者中的生物等效性临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385601.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","IND","02496"],"gpt_icon":0},{"id":"2588031469","title":"友芝友生物-B(02496)于《实验血液学与肿瘤学》上发表M 701恶性腹水II期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2588031469","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588031469?lang=zh_cn&edition=full","pubTime":"2025-12-02 18:09","pubTimestamp":1764670177,"startTime":"0","endTime":"0","summary":"II期研究旨在评估M701腹腔内输注疗法对出现中至大量恶性腹水的晚期上皮性肿瘤患者的疗效与安全性。本研究共纳入84名患者，其中43名患者被分配至M701组，接受腹腔穿刺及腹腔内M701输注。与对照组患者相比，M701组患者的总生存时间获得延长。在M701组别中未观察到任何其他严重不良反应事件。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376609.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"友芝友生物-B(02496)于《实验血液学与肿瘤学》上发表M 701恶性腹水II期数据","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2583665794","title":"深耕双抗领域15年，友芝友生物周鹏飞：中国创新药正在走向产业高潮","url":"https://stock-news.laohu8.com/highlight/detail?id=2583665794","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583665794?lang=zh_cn&edition=full","pubTime":"2025-11-15 13:56","pubTimestamp":1763186186,"startTime":"0","endTime":"0","summary":"M701即将申请上市，友芝友生物将其中国区权益以超过20亿元的预期销售额转让给正大天晴，自己保留海外权益和销售提成。在双抗领域的蓝海中，周鹏飞和他的团队正以坚定的步伐，书写着中国生物医药创新的新篇章。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511151404519505db72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511151404519505db72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","02496","BK1161","BK1574"],"gpt_icon":0},{"id":"2577832867","title":"ORR 72.7%！友芝友生物EpCAM×CD3双抗II期研究中期数据公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2577832867","media":"生物药大时代","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577832867?lang=zh_cn&edition=full","pubTime":"2025-10-20 11:28","pubTimestamp":1760930924,"startTime":"0","endTime":"0","summary":"2025年10月19日，武汉友芝友生物制药股份有限公司宣布，公司自主研发的上皮细胞黏附分子和分化簇3双靶向的在研双特异性抗体药物M701在中国开展的治疗晚期非小细胞肺癌引发的恶性胸水的II期临床研究的中期数据已以大会壁报的形式在2025年欧洲肿瘤内科学会会议上公布。正大天晴将根据研发进展情况，向友芝友生物支付约3.15亿元的首付款及研发里程碑款项，并支付最高不超过7亿元的销售里程碑款项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020113325a4694450&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020113325a4694450&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2576078087","title":"友芝友生物-B(02496)：M701恶性胸水II期研究中期数据在2025年ESMO会议上公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2576078087","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576078087?lang=zh_cn&edition=full","pubTime":"2025-10-19 18:19","pubTimestamp":1760869192,"startTime":"0","endTime":"0","summary":"本研究是一项针对晚期非小细胞肺癌导致的恶性胸水的随机对照、多中心、开放式的II期临床试验。试验组受试者在胸腔穿刺引流后，给予胸腔灌注M701药物。截至2025年3月7日，54名筛选合格的经至少一线全身治疗后病情进展、有症状性恶性胸水的晚期非小细胞肺癌患者，按照1:1随机分组，试验组26名，对照组28名。安全性结果：M701治疗相关不良事件发生率为3.7%，顺铂组为10%，仅1例严重不良事件与M701相关。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2570758200","title":"友芝友生物-B盘中异动 早盘快速拉升5.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2570758200","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570758200?lang=zh_cn&edition=full","pubTime":"2025-09-26 11:26","pubTimestamp":1758857191,"startTime":"0","endTime":"0","summary":"2025年09月26日早盘11时26分，友芝友生物-B股票出现异动，股价急速上涨5.24%。截至发稿，该股报6.630港元/股，成交量6200股，换手率0.01%，振幅5.24%。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。友芝友生物-B股票所在的生物技术行业中，整体跌幅为2.59%。其相关个股中，云康集团、来凯医药-B、友芝友生物-B涨幅较大，振幅较大的相关个股有华昊中天医药-B、创胜集团-B、来凯医药-B，振幅分别为13.57%、11.09%、9.59%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926112631a69f04c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926112631a69f04c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2568427724","title":"友芝友生物-B(02496)：王涛获选举为职工代表监事","url":"https://stock-news.laohu8.com/highlight/detail?id=2568427724","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568427724?lang=zh_cn&edition=full","pubTime":"2025-09-18 16:50","pubTimestamp":1758185448,"startTime":"0","endTime":"0","summary":"智通财经APP讯，友芝友生物-B(02496)发布公告，张敬先生因个人职业发展原因而辞去公司职工代表监事职务，自2025年9月18日起生效。公司研发平台部执行总监王涛博士于2025年9月18日获民主选举为第二届监事会职工代表监事。王涛博士的任期自2025年9月18日起生效，并将于第二届监事会结束时届满。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1346798.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2562849397","title":"友芝友生物-B(02496)发布中期业绩，净亏损5883.4万元，同比收窄25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562849397","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562849397?lang=zh_cn&edition=full","pubTime":"2025-08-26 17:43","pubTimestamp":1756201421,"startTime":"0","endTime":"0","summary":"智通财经APP讯，友芝友生物-B 发布截至2025年6月30日止六个月业绩，收入3718.7万元;净亏损5883.4万元，同比收窄25%;每股基本亏损0.30元。许可费收入主要是公司与正大天晴签订了一项许可合作协定。截至2025年6月30日止六个月，集团就授予许可使用权以实现发展里程碑确认收入470万元。在截至2025年6月30日止六个月，公司根据满足履约义务所付出的努力或投入与预计为满足该履约义务所需的总投入之间的相对比例按进度确认了3250万元的研发服务收入。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1335354.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2517063128","title":"友芝友生物-B盘中异动 大幅下跌8.45%报4.660港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517063128","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517063128?lang=zh_cn&edition=full","pubTime":"2025-03-07 11:41","pubTimestamp":1741318883,"startTime":"0","endTime":"0","summary":"2025年03月07日临近午盘11时41分，友芝友生物-B股票出现异动，股价大幅跳水8.45%。截至发稿，该股报4.660港元/股，成交量600股，换手率0.00%，振幅0.00%。资金方面，该股资金流入0港元，流出2796港元。友芝友生物-B股票所在的生物技术行业中，整体涨幅为0.37%。其相关个股中，云顶新耀-B、百奥赛图-B、金斯瑞生物科技涨幅较大，振幅较大的相关个股有帝王国际投资、创胜集团-B、云顶新耀-B，振幅分别为45.16%、18.09%、15.76%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307114123963cf546&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307114123963cf546&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2517905505","title":"友芝友生物-B盘中异动 快速下挫6.41%报5.400港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517905505","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517905505?lang=zh_cn&edition=full","pubTime":"2025-03-06 10:51","pubTimestamp":1741229469,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘10时51分，友芝友生物-B股票出现波动，股价大幅跳水6.41%。截至发稿，该股报5.400港元/股，成交量1800股，换手率0.00%，振幅2.43%。资金方面，该股资金流入0港元，流出9828港元。最近的财报数据显示，该股实现营业收入数据暂无，净利润-8,589.65万港元，每股收益-0.44港元，毛利数据暂无，市盈率-4.95倍。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。友芝友生物-B股票所在的生物技术行业中，整体涨幅为1.02%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306105109963b8f68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306105109963b8f68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2513313682","title":"友芝友生物-B盘中异动 大幅下挫5.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513313682","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513313682?lang=zh_cn&edition=full","pubTime":"2025-02-21 14:07","pubTimestamp":1740118060,"startTime":"0","endTime":"0","summary":"2025年02月21日下午盘14时07分，友芝友生物-B股票出现异动，股价大幅跳水5.58%。截至发稿，该股报6.600港元/股，成交量2000股，换手率0.00%，振幅1.43%。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。友芝友生物-B股票所在的生物技术行业中，整体涨幅为3.59%。其相关个股中，创胜集团-B、再鼎医药、科伦博泰生物-B涨幅较大，振幅较大的相关个股有创胜集团-B、北海康成-B、三叶草生物-B，振幅分别为20.00%、18.00%、16.22%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221140741962ae8f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221140741962ae8f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2509692752","title":"友芝友生物-B盘中异动 临近午盘急速拉升7.63%报7.900港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509692752","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509692752?lang=zh_cn&edition=full","pubTime":"2025-02-07 11:53","pubTimestamp":1738900381,"startTime":"0","endTime":"0","summary":"2025年02月07日临近午盘11时53分，友芝友生物-B股票出现异动，股价大幅上涨7.63%。截至发稿，该股报7.900港元/股，成交量3600股，换手率0.00%，振幅7.63%。资金方面，该股资金流入2.6536万港元，流出0港元。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。友芝友生物-B股票所在的生物技术行业中，整体跌幅为0.53%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207115302961ab2b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207115302961ab2b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2495639042","title":"友芝友生物-B盘中异动 临近午盘急速拉升10.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2495639042","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495639042?lang=zh_cn&edition=full","pubTime":"2024-12-31 11:49","pubTimestamp":1735616989,"startTime":"0","endTime":"0","summary":"2024年12月31日临近午盘11时49分，友芝友生物-B股票出现波动，股价大幅上涨10.18%。截至发稿，该股报7.900港元/股，成交量5200股，换手率0.00%，振幅17.99%。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。友芝友生物-B股票所在的生物技术行业中，整体跌幅为0.34%。其相关个股中，北海康成-B、宜明昂科-B、友芝友生物-B涨幅较大，振幅较大的相关个股有华昊中天医药-B、华康生物医学、北海康成-B，振幅分别为22.86%、20.00%、19.86%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241231114949ab98dbff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241231114949ab98dbff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02496"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.yzybio.com","stockEarnings":[{"period":"1week","weight":-0.0343},{"period":"1month","weight":-0.0331},{"period":"3month","weight":0.0842},{"period":"6month","weight":0.3571},{"period":"1year","weight":0.0354},{"period":"ytd","weight":-0.0524}],"compareEarnings":[{"period":"1week","weight":-0.0302},{"period":"1month","weight":0.0038},{"period":"3month","weight":0.0121},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.2713},{"period":"ytd","weight":0.0363}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"武汉友芝友生物制药股份有限公司是一家主要从事发现、开发及商业化抗肿瘤双特异性抗体方面的新型创新药物的中国公司。该公司致力于开发用于治疗癌症相关并发症、癌症及老年性眼科疾病的基于双特异性抗体（BsAb）疗法，以解决肿瘤学及老年眼科病领域的医疗需求。该公司的核心产品M701是一种靶向人癌细胞表面抗原EpCAM和人T细胞表面抗原CD3的重组BsAb。该公司的产品管线还包括Y101D、Y332、Y225等。","exchange":"SEHK","name":"友芝友生物-B","nameEN":"YZYBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"友芝友生物-B(02496)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供友芝友生物-B(02496)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"友芝友生物-B,02496,友芝友生物-B股票,友芝友生物-B股票老虎,友芝友生物-B股票老虎国际,友芝友生物-B行情,友芝友生物-B股票行情,友芝友生物-B股价,友芝友生物-B股市,友芝友生物-B股票价格,友芝友生物-B股票交易,友芝友生物-B股票购买,友芝友生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"友芝友生物-B(02496)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供友芝友生物-B(02496)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}